<DOC>
	<DOCNO>NCT00379639</DOCNO>
	<brief_summary>This phase I dose escalation trial design determine maximum tolerate dose ( MTD ) combination romidepsin ( depsipeptide ) gemcitabine . The study originally plan Phase I/II ; however Phase I study conduct .</brief_summary>
	<brief_title>A Study Romidepsin ( Depsipeptide ) Combination With Gemcitabine Patients With Pancreatic Other Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>histologically confirm advanced solid tumor measurable evaluable disease write informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Prior treatment romidepsin gemcitabine Prior chemotherapy treatment within 3 week prior first day treatment prior treatment investigational agent within 4 week prior first day treatment . Patients must recover therapyrelated toxicity ( Common Terminology Criteria grade ≤ 1 ) Prior radiotherapy within 4 week prior first day treatment . Patients fully recover whose acute toxicity relate prior radiotherapy return baseline ineligible . Prior surgery within 3 week prior first day treatment , exclude surgical biopsy port placement Concomitant use anticancer therapy Concomitant use investigational agent Use investigational agent within 4 week study entry Any known cardiac abnormality , include congenital long QT syndrome , QTcF interval &gt; 480 millisecond , myocardial infarction within 12 month study entry , coronary artery disease ( CAD ) , congestive heart failure ( CHF ) , evidence cardiac ischemia screening , know history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest , hypertrophic cardiomegaly restrictive cardiomyopathy chronic hypertension , cardiac arrhythmia require antiarrhythmic medication Serum potassium &lt; 3.8 mmol/L serum magnesium &lt; 2.0 mg/dL ( electrolyte abnormality correct supplementation meet inclusion criterion ) Concomitant use drug may cause prolongation QTc Concomitant use CYP3A4 inhibitor Clinically significant active infection Known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Inadequate bone marrow organ function evidence : Hemoglobin &lt; 9 g/dL ( Transfusions and/or erythropoietin permit . ) Absolute neutrophil count ( ANC ) ≤1.5 x 10^9 cells/L Platelet count &lt; 100 x 10^9 cells/L platelet count &lt; 75 x 10^9 cells/L bone marrow disease involvement document Total bilirubin &gt; 2.0 x upper limit normal ( ULN ) Aspartate transaminase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 2.0 x ULN &gt; 3.0 x ULN presence demonstrable liver metastasis Serum creatinine &gt; 2.0 x ULN Patients pregnant breastfeed Any significant medical psychiatric condition might prevent patient comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>